![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Clade Therapeutics
Main focus: Novel stem cell-derived cellular therapies
Company stage: Pre-clinical
Diseases: Undisclosed
Genome editing tool: Undisclosed
Funding stage: Private
Location: Cambridge, MA, USA
Website: https://cladetx.com/
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_clade-therapeutics-color_402x_d6f547c6e0_84a84c0b48.png)
Clade Therapeutics is focused on the development of next-generation cellular therapies, applying its induced pluripotent stem cell (iPSC)-based platform. Using its technology, it is able to generate iPSC-derived adult T, natural killer (NK) and B cells. The company is co-founded by Chad Cowan, a CRISPR Therapeutics co-founder, however, exactly how gene editing is used in the cell therapies under development has not yet been undisclosed.